A 62-Year-Old Woman with Muscle Weakness.

A 62-year-old woman noticed muscle weakness in the right leg, which was followed a few months later by weakness in the left leg. Over a 6-month period, the muscle weakness progressed to the upper limbs. One year after onset, the patient was referred to a neurologist with a suspected diagnosis of amyotrophic lateral sclerosis. She was taking atorvastatin 40 mg (started approximately 6 years earlier) and l-thyroxine 125 μg (for hypothyroidism after nuclide therapy for Graves disease). Clinical examination revealed a proximal paresis in the arms and legs. Creatine kinase (CK)5 activity was 7925 U/L (reference interval <145 U/L). Electromyography showed myogenic changes (small and polyphasic motor units). A toxic statin myopathy was considered, although the time span between the start of the statin and onset of the symptoms was long. Late-onset Pompe (glycogen storage) disease was excluded by α-glucosidase activity testing. Further laboratory testing was unremarkable. A biopsy of the right quadriceps muscle was performed and revealed polygonal muscle fibers of varying diameter (and an increase of internal nuclei). There was some evidence of endomysial fibrosis without inflammatory infiltration. Individual muscle fibers showed necrosis with myocyte phagocytosis and without HLA-ABC upregulation. ### PATIENT FOLLOW-UP The muscle weakness was progressive and also affected distal hand muscles and bulbar muscles. The use of statins was discontinued, and high-dose intravenous methylprednisolone was given, followed by oral tapering. Ten days later, there was only minor improvement of the muscle weakness, and azathioprine 100 mg per day was added. Ezetimibe and fenofibrate were started for hypercholesterolemia. The weakness improved, CK …

[1]  W. Stenzel,et al.  Immune-mediated necrotizing myopathy , 2016, Zeitschrift für Rheumatologie.

[2]  Richard G. Fowler,et al.  Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies , 2014, Journal of immunology research.

[3]  A. Mammen,et al.  Statin‐associated autoimmune myopathy and anti‐HMGCR autoantibodies , 2013, Muscle & nerve.

[4]  Y. Allenbach,et al.  [Acquired necrotizing myopathies]. , 2013, La Revue de medecine interne.

[5]  A. Mammen,et al.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. , 2012, Arthritis and rheumatism.

[6]  A. Mammen,et al.  Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl‐coenzyme A reductase–associated autoimmune myopathy , 2012, Arthritis care & research.

[7]  A. Mammen,et al.  Rarity of anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in statin users, including those with self‐limited musculoskeletal side effects , 2012, Arthritis care & research.

[8]  A. Mammen,et al.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. , 2011, Arthritis and rheumatism.

[9]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[10]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.